Vergence/accommodative therapy for symptomatic convergence insufficiency in children: Time course of improvements in convergence function. (22nd October 2022)

• Record Type: Journal Article
• Authors: Jenewein, Erin C.; Cotter, Susan; Roberts, Tawna; Kulp, Marjean; Mitchell, G. Lynn; Jones‐Jordan, Lisa A.; Chen, Angela M.; Hopkins, Kristine; Huang, Kristine; Amster, Deborah; Fecho, Gregory; Tyler, Julie; Meiyeppen, Shivakhaami; Scheiman, Mitchell
• Other Names: Cooper Jeffrey investigator.; Schulman Erica investigator.; Hamian Kimberly investigator.; Iacono Danielle investigator.; Larson Steven investigator.; Leung Valerie investigator.; Meeder Sara investigator.; Ramos Elaine investigator.; Ritter Steven investigator.; Steiner Audra investigator.; Stormann Alexandria investigator.; Vricella Marilyn investigator.; Zhu Xiaoying investigator.; Tamkins Susanna investigator.; Aguilera Naomi investigator.; Brafman Elliot investigator.; Capo Hilda investigator.; Cavuoto Kara investigator.; Crespo Isaura investigator.; Dowling Monica investigator.; Draskovic Kristie investigator.; Farag Miriam investigator.; Fischer Vicky investigator.; Grace Sara investigator.; Gutierrez Ailen investigator.; Manchola‐Orozco Carolina investigator.; Martinez Maria investigator.; McKeown Craig investigator.; Osigian Carla investigator.; Pham Tuyet‐Suong investigator.; Small Leslie investigator.; Townsend Natalie investigator.; Gallaway Michael investigator.; Boas Mark investigator.; Calvert Christine investigator.; Franz Tara investigator.; Gerrouge Amanda investigator.; Hayden Donna investigator.; Margolies Zachary investigator.; Myung Jenny investigator.; Pollack Karen investigator.; Shoge Ruth investigator.; Tang Andrew investigator.; Tannen Noah investigator.; Trieu Lynn investigator.; Trujillo Luis investigator.; Buckland Michelle investigator.; Ellis Allison investigator.; Fogt Jennifer investigator.; McDaniel Catherine investigator.; McGann Taylor investigator.; Morrison Ann investigator.; Mulvihill Shane investigator.; Peiffer Adam investigator.; Plaumann Maureen investigator.; Pierce Gil investigator.; Preston Julie investigator.; Reuter Kathleen investigator.; Stevens Nancy investigator.; Teeny Jake investigator.; Toole Andrew investigator.; Widmer Douglas investigator.; Zimmerman Aaron investigator.; Barnhardt Carmen investigator.; Borsting Eric investigator.; Chu Raymond investigator.; Parker Susan investigator.; Retnasothie Dashaini investigator.; Wu Judith investigator.; Hertle Richard investigator.; Clark Penny investigator.; Culp Kelly investigator.; Fraley Kathy investigator.; Grant Drusilla investigator.; Hanna Nancy investigator.; Knox Stephanie investigator.; Lawhon William investigator.; Li Lan investigator.; Mitcheff Sarah investigator.; Ricker Isabel investigator.; Solis Casandra investigator.; Wall Palak investigator.; Zaczyk Samantha investigator.; Marsh‐Tootle Wendy investigator.; Bowen Michelle investigator.; Call Terri investigator.; Domnanovich Kristy investigator.; Frazier Marcela investigator.; Guyette Nicole investigator.; Hayes Oakley investigator.; Houser John investigator.; Lee Sarah investigator.; Montejo Jenifer investigator.; Oechslin Tamara investigator.; Turner Candace investigator.; Weise Katherine investigator.; Coulter Rachel investigator.; Bade Annette investigator.; Bansal Surbhi investigator.; Falco Laura investigator.; Green Katherine investigator.; Irizarry Gabriela investigator.; Jhajj Jasleen investigator.; Patterson Nicole investigator.; Rodena Jacqueline investigator.; Tea Yin investigator.; Weiss Dana investigator.; Zakaib Lauren investigator.; Lorenzana Ingryd investigator.; Meza Yesena investigator.; Mann Ryan investigator.; Quezada Mariana investigator.; Rein Scott investigator.; Rudaitis Indre investigator.; Stepleton Susan investigator.; Wajs Beata investigator.; Redford Maryann investigator.; Hertle Richard investigator.; Redford Maryann investigator.; Denton Carolyn investigator.; Arnold Eugene investigator.; Borsting Eric investigator.; Chase Christopher investigator.; Denton Carolyn investigator.; Wee Sharyl investigator.; Dahl‐Leonard Katlynn investigator.; Powers Kenneth investigator.; Alaniz Amber investigator.; Diener‐West Marie investigator.; Good William V. investigator.; Grisham David investigator.; Kratochvil Christopher J. investigator.; Revicki Dennis investigator.; Wanzek Jeanne investigator.; Pollack Karen investigator.; Abraham Mustafa investigator.; Dangelo Julianne investigator.; Hegedus Jordan investigator.; Jones Ian investigator.; Junglas Alexander investigator.; Lee Jihyun investigator.; Nettles Jadin investigator.; Mitchell Curtis investigator.; Osman Mawada investigator.; Scott‐Tibbs Gloria investigator.; Sinnott Loraine investigator.; Teasley Chloe investigator.; Vang Victor investigator.; Varghese Robin investigator.;
• Is Part Of: Ophthalmic and physiological optics. Volume 43:Number 1(2023)
• Page Start: 105
• Page End: 115
• Publication Date: 2022-10-22
• Subjects: convergence insufficiency -- near‐point of convergence -- positive fusional vergence -- treatment kinetics -- vergence/accommodative therapy; Ophthalmology -- Periodicals; Physiological optics -- Periodicals; Optometry -- Periodicals; Optics -- Periodicals; Vision -- Periodicals; 617.75
• DOI: 10.1111/opo.13062
• Languages: English
• ISSNs: 0275-5408

Abstract

Abstract: Purpose: To evaluate the time course of improvements in clinical convergence measures for children with symptomatic convergence insufficiency treated with office‐based vergence/accommodative therapy. Methods: We evaluated convergence measures from 205, 9‐ to 14‐year‐old children with symptomatic convergence insufficiency randomised to office‐based vergence/accommodative therapy in the Convergence Insufficiency Treatment Trial – Attention and Reading Trial (CITT‐ART). Near‐point of convergence (NPC) and near‐positive fusional vergence (PFV) were measured at baseline and after 4, 8, 12 and 16 weeks of therapy; mean change in NPC and PFV between these time points were compared using repeated measures analysis of variance. Rates of change in NPC and PFV from: (1) baseline to 4 weeks and (2) 4–16 weeks were calculated. For each time point, the proportion of participants to first meet the normal criterion for NPC (<6 cm), PFV blur (break if no blur; >15Δ and >2 times the exodeviation) and convergence composite (NPC and PFV both normal) were calculated. Results: The greatest change in NPC and PFV (7.6 cm and 12.7 Δ) and the fastest rate of improvement in NPC and PFV (1.9 cm/week and 3.2 Δ/week, respectively) were both found during the first 4 weeks of therapy, with both slowing over the subsequent 12 weeks. After 12 weeks of therapy, the NPC, PFV and convergence composite were normal in 93.2%, 91.7% and 87.8% of participants, respectively, and normalised with another 4 weeks of therapy in 4.4%, 2.0% and 4.4% of participants, respectively. Conclusion: Although the greatest improvements in NPC and PFV occurred in the first 4 weeks of therapy, most participants had weekly improvements over the subsequent 12 weeks of treatment. While most children with convergence insufficiency obtained normal convergence following 12 weeks of therapy, an additional 4 weeks of vergence/accommodative therapy may be beneficial for some participants.